Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Swiss pharmaceutical giant Novartis (SIX:NOVN) has reaffirmed its commitment to producing life-saving treatments for malaria and leprosy, even amid uncertainty over global health funding. According to Dr. Lutz Hegemann, President of Global Health at Novartis, the company will continue manufacturing its 28 million annual malaria treatment courses regardless of demand or funding disruptions.
Most of Novartis' antimalarial drugs are sold at a not-for-profit price to global initiatives, including the U.S.-funded President’s Malaria Initiative (PMI). However, recent aid cuts under President Donald Trump have threatened such programs. Earlier this year, a contractor for PMI canceled an order due to a government stop-work directive, but resumed the request shortly after receiving an exemption. “We are not going to be the bottleneck,” said Hegemann, emphasizing the company's commitment to maintaining supply even during funding gaps.
The Global Fund to Fight AIDS, Tuberculosis and Malaria remains the largest purchaser of Novartis' malaria treatments. While it has not yet faced funding cuts, it is actively seeking donations in a difficult financial environment.
Speaking from London, Hegemann urged the pharmaceutical industry to take a more proactive role in global health, advocating for deeper collaborations with low- and middle-income countries. He stressed that companies should go beyond merely compensating for shrinking donor aid and instead foster long-term public-private partnerships.
Novartis is also ramping up its R&D spending on malaria and neglected tropical diseases. The company expects to invest $490 million by 2025—nearly double its original $250 million pledge. Ongoing projects include a dengue antiviral, new therapies for leishmaniasis and Chagas disease, and the first malaria drug designed for newborns.
This strong commitment highlights Novartis’ leadership in global health and its resolve to support vulnerable communities worldwide.
